Physician profile
Keith R Wolfson
NPI 1417047275
$3,051.26
in general payments reported to CMS, 2019-2025
24 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $347 · 2021: $391 · 2022: $626 · 2023: $406 · 2024: $288 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $545.37 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $500.12 | 2019-2022 | |
| Boston Scientific Corporation | $479.41 | 2022-2025 | Watchman Flx, Farapulse, Watchman Access System |
| Amgen INC. | $229.89 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $217.64 | 2019-2025 | |
| Abbott Laboratories | $183.12 | 2020-2024 | Mitraclip |
| Pfizer INC. | $171.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $123.24 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $106.56 | 2021-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $71.98 | 2019-2023 | |
| Philips North America LLC | $66.58 | 2023 | |
| Edwards Lifesciences Corporation | $57.28 | 2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $45.58 | 2022 | |
| Amarin Pharma, INC. | $42.03 | 2019 | |
| Kestra Medical Technology Services, INC. | $39.91 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.59 | 2019-2023 | Lifevest |
| Esperion Therapeutics, INC. | $25.61 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $21.22 | 2022 | |
| Lantheus Medical Imaging, INC. | $17.07 | 2023 | Definity |
| Abbvie INC. | $14.92 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.97 | 2022 | |
| Astellas Pharma US INC | $13.73 | 2019 | |
| Recor Medical INC | $13.57 | 2024 | Paradise Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.